Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Portfolio Pulse from
Capricor Therapeutics has submitted a Biologics License Application to the FDA for deramiocel, a potential treatment for Duchenne muscular dystrophy cardiomyopathy. Approval could make it the first therapy for this condition and trigger a $10 million payment from Nippon Shinyaku.
January 02, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics has completed its BLA submission to the FDA for deramiocel, targeting Duchenne muscular dystrophy cardiomyopathy. Approval could lead to a $10 million milestone payment from Nippon Shinyaku.
The submission of the BLA is a significant milestone for Capricor, as approval would not only validate their product but also trigger a substantial financial milestone. This news is likely to positively impact CAPR's stock price in the short term due to the potential for market approval and financial gain.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100